Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Rangering i aksjer #31255
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Aksjekurs
$0.39
Markedsverdi
$13.79M
Endring (1 dag)
-13.53%
Endring (1 år)
-68.80%
Land
IL
Handel NeuroSense Therapeutics Ltd. (NRSN)

Kategori

Utbyttehistorikk for NeuroSense Therapeutics Ltd. (NRSN)
NeuroSense Therapeutics Ltd. (aksjesymbol: NRSN) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for NeuroSense Therapeutics Ltd. (NRSN) fra 2026 til 2026
Årlige utbyttebetalinger
År Utbytte (justert for aksjesplitt) Endre
Ikke nok data for de angitte datoene.
Liste over alle utbyttebetalinger
År Utbytte Endre
Ikke nok data for de angitte datoene.
Utbyttebetalinger for lignende selskaper eller konkurrenter
Selskap Antall utbyttebetalinger Land
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH
29.00%
BE